Biogen asks why Ireland won’t fund new spinal muscular atrophy drug

Biogen asks why Ireland won’t fund new spinal muscular atrophy drug

Biogen is also urgently calling on the HSE to reform the appraisal process for orphan medicines to treat rare diseases, arguing that there is a need for a greater degree of flexibility for these assessments

Biogen Ireland has called on Minister for Health Simon Harris to explain why Ireland joined an EU pharma partnership yet remains the only country in the partnership refusing to fund Biogen’s drug.

Ireland joined the partnership, called BeNeLuxA (Belgium, Netherlands, Luxembourg, Austria) in June. It aims to jointly negotiate pharmaceutical deals.

The partnership recently reached its first collective pricing agreement on Spinraza, which is used to treat Spinal Muscular Atrophy (SMA) – a debilitating,...

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post